Johnson & Johnson的肺癌治疗结果比AstraZeneca的主要药物要好。 Johnson & Johnson's lung cancer treatment shows better results than AstraZeneca's leading drug.

与AstraZeneca的osimertinib相比,Johnson & Johnson的Rybrevant的Rybrevant与Lazcluze在治疗某种特定类型的肺癌方面取得了更好的结果,JNJ药物组合中的病人有更长的中位存活时间。 Johnson & Johnson's Rybrevant, combined with Lazcluze, has shown better results in treating a specific type of lung cancer compared to AstraZeneca's osimertinib, with patients on the JNJ drug combination having a longer median survival time. 同时,分析家认为,GeneDx是一个不太为人所知的保健存量,由于其在基因测试方面的显著增长和竞争性定价,可能值得投资。 Meanwhile, analysts suggest that GeneDx, a lesser-known healthcare stock, could be worth investing in due to its significant growth and competitive pricing in genetic testing. 此外,林业发展局还批准了Exelixis' Cabometyx治疗某些类型的神经内分泌肿瘤,扩大了先前的核准范围。 Additionally, the FDA approved Exelixis' Cabometyx for treating certain types of neuroendocrine tumors, expanding its previous approvals.